The patient’s lab tests told the whole story.
His alkaline phosphatase, a measure of liver health, decreased from 313 units/liter in April back into the normal range below 120 just one month later. An MRI at that time showed that the numerous metastatic tumors in his liver had completely vanished. This patient’s metastatic bladder cancer had responded profoundly to treatment with Padcev (enfortumab vedotin), a new antibody-drug conjugate (ADC) drug that received accelerated approval from the FDA in 2019.
The patient with this miraculous response is my father.